Perinatal Mononuclear Cells for Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The clinical translation of stem cell populations for therapeutic applications, such as cancer treatments, is limited due to allogenic issues and the need for effective immune modulation and regenerative properties.
Innovation Solution
Isolation and use of perinatal tissue-derived mononuclear cells (CMNCs) with specific markers and immune modulatory properties, including immune modulatory, neurogenic, anti-inflammatory, and angiogenic activities, which are plastic adherent and express specific surface markers like CD73, CD37, and CD69, and produce cytokines like IL-10 and HLA-G.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell populations are used for therapeutic applications, then regenerative and immune modulatory properties are improved, but allogenic issues and immune rejection risks worsen
Solution Approach 1:
The patent uses autologous perinatal tissue-derived mononuclear cells (PMNCs) that are genetically identical to the patient's own cells, eliminating allogenic rejection. The cells are isolated from the patient's perinatal tissue and cultured to expand the population while maintaining genetic homogeneity with the host, thus resolving the contradiction between therapeutic efficacy and immune rejection risk.
Solution Approach 2:
The patent employs perinatal tissue-derived mononuclear cells as an intermediary therapeutic agent that mediates immune modulation and regenerative effects. These cells serve as a bridge between the patient's own tissue and the therapeutic outcome, providing immune modulatory properties while avoiding allogenic issues since they are autologous in origin.
2Reliability
If perinatal tissue-derived mononuclear cells are isolated and cultured, then immune modulatory and regenerative capabilities are enhanced, but isolation and culture complexity increases
Solution Approach 1:
The patent isolates perinatal tissue-derived mononuclear cells that possess multiple functions including immune modulatory, regenerative, anti-inflammatory, and angiogenic activities. This multi-functionality allows a single cell population to address multiple therapeutic needs simultaneously, reducing the complexity of requiring multiple different cell types or treatments while maintaining enhanced therapeutic capabilities.
Solution Approach 2:
The patent optimizes culture conditions by changing physical and chemical parameters such as using specific growth media formulations, controlling oxygen tension, and adjusting pH levels to enhance the immune modulatory and regenerative capabilities of PMNCs. These parameter changes improve cell functionality while streamlining the culture process to reduce overall complexity.
3Adaptability or versatility
If cells are selected for specific markers like CD73, CD37, and CD69, then cell population specificity and therapeutic targeting are improved, but isolation precision requirements worsen
Solution Approach 1:
The patent uses flow cytometry-based marker detection where fluorescently labeled antibodies bind to specific cell surface markers (CD73, CD37, CD69) on perinatal tissue-derived mononuclear cells. The fluorescent signals act as optical identifiers that allow precise identification and selection of cells expressing the desired marker profile, improving population specificity while managing isolation precision through automated optical detection rather than manual methods.
Data Source
AI summary
Cell populations and methods of use of mononuclear cells (CMNCs) obtained from dissociated vascular lobules of a perinatal tissue cultured to confluency under hypoxia sufficient to induce translocation of HIF-1 alpha.